Valbiotis (ALVAL) Stock Overview
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ALVAL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Valbiotis SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.69 |
| 52 Week High | €1.68 |
| 52 Week Low | €0.54 |
| Beta | -0.43 |
| 1 Month Change | -3.50% |
| 3 Month Change | -14.81% |
| 1 Year Change | -56.05% |
| 3 Year Change | -81.89% |
| 5 Year Change | -89.82% |
| Change since IPO | -93.10% |
Recent News & Updates
Recent updates
Does Valbiotis (EPA:ALVAL) Have A Healthy Balance Sheet?
Nov 19
Here's Why We Think Valbiotis SA's (EPA:ALVAL) CEO Compensation Looks Fair
Apr 11Is Valbiotis (EPA:ALVAL) A Risky Investment?
Jun 20Rock star Growth Puts Valbiotis (EPA:ALVAL) In A Position To Use Debt
May 09Is Valbiotis (EPA:ALVAL) Using Debt In A Risky Way?
May 10Valbiotis SA (EPA:ALVAL) Is Expected To Breakeven In The Near Future
Mar 08Shareholder Returns
| ALVAL | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -0.6% | -13.9% | 1.2% |
| 1Y | -56.1% | 306.9% | 8.9% |
Return vs Industry: ALVAL underperformed the French Biotechs industry which returned 347.3% over the past year.
Return vs Market: ALVAL underperformed the French Market which returned 9.2% over the past year.
Price Volatility
| ALVAL volatility | |
|---|---|
| ALVAL Average Weekly Movement | 17.9% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 10.1% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALVAL's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALVAL's weekly volatility has increased from 11% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 44 | Sebastien Peltier | www.valbiotis.com |
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis.
Valbiotis SA Fundamentals Summary
| ALVAL fundamental statistics | |
|---|---|
| Market cap | €16.32m |
| Earnings (TTM) | -€11.11m |
| Revenue (TTM) | €474.00k |
Is ALVAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALVAL income statement (TTM) | |
|---|---|
| Revenue | €474.00k |
| Cost of Revenue | €2.35m |
| Gross Profit | -€1.87m |
| Other Expenses | €9.24m |
| Earnings | -€11.11m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | -394.94% |
| Net Profit Margin | -2,344.94% |
| Debt/Equity Ratio | 35.9% |
How did ALVAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/08 12:49 |
| End of Day Share Price | 2026/01/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Valbiotis SA is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mohamed Kaabouni | Portzamparc BNP Paribas |
| Corentin Marty | TPICAP Midcap |